Patent Deal Clears Actavis' Zohydro Generic For 2029

Law360, New York (January 29, 2018, 8:23 PM EST) -- Actavis Laboratories FL Inc. will be able to launch its generic version of the hydrocodone-based painkiller Zohydro ER in March 2029, Pernix Therapeutics Holdings Inc. announced Monday as part of a settlement ending patent infringement litigation in Delaware federal court.

In March 2016, Pernix accused Actavis of infringing six of its patents tied to the opioid by filing a request with the U.S. Food and Drug Administration to get its generic approved. Monday’s settlement ends that litigation, but its terms other than the licensing date are...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Pernix Ireland Pain Ltd. et al v. Actavis Laboratories FL, Inc.


Case Number

1:16-cv-00138

Court

Delaware

Nature of Suit

Patent

Judge

Gregory M. Sleet

Date Filed

March 4, 2016


Case Title

Recro Gainesville LLC v. Actavis Laboratories FL, Inc.


Case Number

17-1822

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

March 22, 2017


Case Title

Recro Gainesville LLC v. Actavis Laboratories FL, Inc.


Case Number

1:17-cv-01535

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Judge

Gregory M. Sleet

Date Filed

October 30, 2017

Law Firms

Companies

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.